.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Follicular lymphoma remains a common yet complex malignancy. This disease often follows an indolent course but frequently results in repeated relapses. Consequently, patients often experience progressively shorter responses with each successive line of therapy. Recently, odronextamab follicular lymphoma treatment has emerged as a promising chemo-free approach for relapsed or refractory cases. This bispecific antibody specifically targets CD20 and CD3 to harness the patient's own immune system.
The clinical development of odronextamab centers on the pivotal ELM-1 and ELM-2 studies. These trials investigated its safety and anti-tumor activity in heavily pretreated patients. Specifically, the phase II ELM-2 trial reported an objective response rate (ORR) of approximately 80% in the follicular lymphoma cohort. Furthermore, over 70% of these patients achieved a complete response. These durable results led to its conditional approval by the European Medicines Agency (EMA). Moreover, researchers are now evaluating its performance in earlier lines of therapy via the OLYMPIA trial program.
The therapeutic mechanism involves simultaneously binding to CD20 on malignant B-cells and CD3 on T-cells. This dual engagement facilitates potent T-cell-mediated cytotoxicity against the lymphoma cells. Although the efficacy is high, clinicians must manage specific adverse events like cytokine release syndrome (CRS). Most cases of CRS occur early during treatment and are generally manageable with step-up dosing and prophylaxis. Additionally, ongoing studies like OLYMPIA-1 and OLYMPIA-5 are exploring combinations with agents like lenalidomide to improve outcomes further. Therefore, odronextamab represents a significant shift toward precision immunotherapy in hematological oncology.
Unlike rituximab, which is a monoclonal antibody, odronextamab is a bispecific antibody. It does not just mark cells for destruction; it actively pulls T-cells into direct contact with cancer cells to trigger a kill response.
Currently, regulatory approval focuses on relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. However, ongoing phase III trials are investigating its use in earlier and frontline settings.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Odronextamab, a novel bispecific antibody, is transforming the care of relapsed/refractory follicular lymphoma. Following its EMA approval, this review highlights its impressive efficacy in the ELM trials and explores its future role in earlier lines of therapy.
2 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
